Seelos Therapeutics

Healthcare | Biotechnology | USA

SEEL nachbörslich 25% nach oben auf aktuell 3.68:

Seelos Therapeutics Provides Update on Pipeline Developments and Corporate Highlights

- First patient with Sanfilippo Syndrome expected to be dosed with Trehalose in an open-label phase IIb trial in 2Q 2019 –

- Plan to initiate phase I study with intranasal racemic ketamine in Suicidality-PTSD in the summer of 2019–

- Proof of concept for Target Engagement for peptide-based approach targeting the NACore in Parkinson’s Disease expected to begin in 2Q 2019 –

- Management to share archived webcast of interview with the TD Ameritrade Network –

...

https://finance.yahoo.com/news/seelos-th...00285.html